Hsp90 family protein inhibitors
View Patent ↗The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoic acid derivative represented by General Formula (I): [wherein n represents an integer of 0 to 10; R 1 represents substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted aroyl, or the like; R 2 represents —NR 14 R 15 (wherein R 14 and R 15 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl or the like); R 3 and R 5 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl or the like; and R 4 and R 6 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl or the like] or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoic acid derivative or said prodrug.
1. A method for inhibiting heat shock protein 90 family protein comprising administering, to a patient in need thereof, an effective amount of a compound represented by Formula (I):
(wherein n represents an integer of 0 to 2;
R 1 represents a hydrogen atom, hydroxy, substituted or unsubstituted lower alkoxycarbonyl, or —OR 13 (wherein R 13 represents substituted or unsubstituted lower alkyl, or substituted or unsubstituted aralkyl;
R 2 represents —NR 14 R 15 (wherein R 14 and R 15 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heterocyclic alkyl, or R 14 and R 15 are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or —OR 16 (wherein R 16 represents substituted or unsubstituted lower alkyl);
R 3 , R 4 and R 5 each represents a hydrogen atom; and
R 6 represents a hydrogen atom, halogen, or substituted or unsubstituted lower alkyl,
or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 , wherein R 1 is substituted or unsubstituted lower alkoxycarbonyl.
3. The method according to claim 1 , wherein R 1 is —OR 13 .
4. The method according to any one of claims 1 , 2 and 3 , wherein R 2 is —NR 14b R 15b (wherein R 14b and R 15b independently represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heterocyclic alkyl).
5. The method according to any one of claims 1 , 2 and 3 , wherein R 2 is —NR 14c R 15c (wherein R 14c and R 15c are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group).
6. A method for treating mammary cancer, comprising administering, to a patient in need thereof, an effective amount of the compound, or said pharmaceutically acceptable salt thereof described in claim 1 .
7. A method for treating leukemia, comprising administering, to a patient in need thereof, an effective amount of the compound, or said pharmaceutically acceptable salt thereof described in claim 1 .
8. A method for treating chronic myelocytic leukemia, comprising administering, to a patient in need thereof, an effective amount of the compound, or said pharmaceutically acceptable salt thereof described in claim 1 .